Skip to content

Orphan Drugs: Top 2013 Selling Drugs Launched

May 19, 2014

.

.

Last week, GEN (Genetic Engineering & Biotechnology News), publishes an online list of the top 18 best-selling drugs that are launched in 2013, for those companies who provide 2013 sales information.

The chart below shows the 8 orphan drugs and the following data fields:

•   GEN ranking out of 18

•     Manufacturer

•     2013 Sales in $Millions

•     FDA and EC approval dates

•     Indication.

Top 8 Selling Orphan Drugs Launched in 2013

GEN # Product Manufacturer 2013 Sales FDA App/EC App Dts Indication
2 Pomalyst (Pomalidomide) Celgene $305 02.08.13/ 08.09.13 Multiple Myeloma
6 Juxtapid (Lomitapide) Aegerion Pharmaceuticals $48.5 12.21.12/ 07.31.13 Homozygous  Familial

Hypercholester-olemia (HoFH)

7 Iclusig (Ponatinib) Ariad Pharmaceuticals $45.2 12.14.12/ 07.03.13 CML/ Ph+ ALL
10 Gattex (Teduglutide) NPS Pharmaceuticals $31.8 12.21.12/ 08.30.12 Short Bowel

Syndrome (SBS)

11 Tafinlar (Dabrafenib) * GlaxoSmithKline $26.9 05.29.13/ 09.02.13 Metastatic

Melanoma

with

BRAF V600E

mutation

13 Mekinist (Trametinib) * GlaxoSmithKline $16.8 05.29.13/ 09.02.13 Metastatic

Melanoma

with

BRAF V600E

or V600K

mutations

14 Imbruvica (Ibrutinib) ** Pharmacyclics/ Janssen Biotech $13.6 11.13.13/ Seeking EC approval Mantle Cell

Lymphoma (MCL) ***

16 Opsumit (Macitentan) Actelion Pharmaceuticals $5.68 10.18.13/ 12.20.13 Pulmonary Arterial Hypertension (PAH, WHO Group I)

.

*  FDA Approval of Tafinlar & Mekinist combination – 01.08.14 & 01.09.14

** Receives FDA Breakthrough Therapy Designation (BTD)

*** Receives FDA Approval for CLL 02.12.14 & seeking EC approval for CLL/SLL/MCL

For non-orphan drug rankings, please reference the article.

Observations

•   Of the top 18 best sellers, 8 or approximately 44% are for orphan drugs

•   5 of the 8 (62.5%) orphan drugs are for an oncology indication

•   GlaxoSmithKline has 2 orphan drugs

•   The article identifies several companies that decline to disclose 2013 sales:

  1. Sanofi/Isis Pharmaceuticals’ orphan drug Kynamro for HoFH
  2. Bayer’s orphan drug Adempas for Pulmonary Hypertension
  3. Boehringer Ingelheim’s orphan drug Gilotrif for EGFR NSCLC.

Please Note: “Abstract pills” by Robson# (Flickr: Pills here) [CC-BY-2.0] | Wikimedia Commons.

Copyright © 2012-2014, Orphan Druganaut Blog. All rights reserved.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: